Does SERCA2a gene therapy reduce sarcoplasmic reticulum calcium leak and ventricular arrhythmias in a model of chronic heart failure?
SERCA2a gene transfer reduces sarcoplasmic reticulum calcium leak and ventricular arrhythmias in a heart failure model, suggesting a potential novel antiarrhythmic strategy.
SERCA2a gene therapy stabilizes SR Ca(2+) load, reduces ryanodine receptor phosphorylation and decreases SR Ca(2+) leak, and reduces cellular triggered activity in vitro and spontaneous and catecholamine-induced ventricular arrhythmias in vivo in failing hearts. SERCA2a gene therapy did not therefore predispose to arrhythmias and may represent a novel antiarrhythmic strategy in heart failure.
Lyon et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: